Европейски съюз - чешки - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol fosfát z haemophilus influenzae typu b, jako prp-ompc, vnější membránový proteinový komplex neisseria meningitidis (vnější membránový proteinový komplex b11 kmen neisseria meningitidis podskupina b), adsorbovaná hepatitis b surface antigen produkovaný v rekombinantních kvasinkových buněk (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - vakcíny - procomvax je indikován k očkování proti invazivním onemocněním, které způsobuje haemophilus influenzae typu b a proti infekci způsobené všemi známými podtypy viru hepatitidy b u kojenců 6 týdnů do 15 měsíců věku.

Европейски съюз - чешки - EMA (European Medicines Agency)

merck sharp & dohme b.v. - fosfát tedizolidu - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.

Европейски съюз - чешки - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinom, plicní jiná než malobuněčná - antineoplastická činidla - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline biologicals s.a., rixensart array - 14766 povrchovÝ antigen hepatitidy b - injekční suspenze - 10mcg - hepatitida b, purifikovanÝ antigen

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

glaxosmithkline biologicals s.a., rixensart array - 14766 povrchovÝ antigen hepatitidy b - injekční suspenze - 20mcg - hepatitida b, purifikovanÝ antigen

Европейски съюз - чешки - EMA (European Medicines Agency)

amgen europe b.v. - talimogene laherparepvec - melanom - antineoplastická činidla - imlygic je indikován k léčbě dospělých pacientů s neresekovatelným melanomem, která je regionálně nebo vzdáleně metastatickým (stadium iiib, iiic a ivm1a) s bez kostí, mozku, plic nebo jiných viscerální onemocnění.

Европейски съюз - чешки - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. viz kapitoly 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Европейски съюз - чешки - EMA (European Medicines Agency)

merck sharp & dohme b.v. - vakcína proti lidskému papilomaviru (typy 6, 11, 16, 18, 31, 33, 45, 52, 58) (rekombinantní, adsorbovaná) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - vakcíny proti papilomaviru - přípravek gardasil 9 je indikován k aktivní imunizaci jedinců od věku 9 let proti následujícím hpv onemocnění:prekancerózní léze a karcinomy, které ovlivňují děložního čípku, vulvy, pochvy a konečníku způsobené hpv obsaženými ve vakcíně typesgenital bradavice (condyloma acuminata) způsobené specifickými typy hpv. viz kapitoly 4. 4 a 5. 1 pro důležité informace o údajích, které podporují tyto údaje. použití přípravku gardasil 9 musí být v souladu s oficiálními doporučeními.

Европейски съюз - чешки - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastická činidla - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Европейски съюз - чешки - EMA (European Medicines Agency)

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastická činidla - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.